Form 4: Heron Therapeutics, Inc. /De/ Executive Reports Stock Transa
Insider Transaction (Form 4)
William P Forbes, EVP, Chief Development Officer of Heron Therapeutics, Inc. /De/, reported multiple transactions in common stock on July 19, 2026.
Summary
- Option exercise/conversion: acquired 3,874 Common Stock on July 19, 2026; holds 225,485 after (Direct).
- Tax/exercise-price withholding: disposed of 1,101 Common Stock at $0.47 ($517) on July 19, 2026; holds 224,384 after (Direct).
- Option exercise/conversion: disposed of 3,874 Restricted Stock Units on July 19, 2026; holds 23,246 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
William P Forbes — Officer (EVP, Chief Development Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-19 | Option exercise/conversion | Common Stock | 3,874 | — | — | 225,485 |
| 2026-07-19 | Tax/exercise-price withholding | Common Stock | 1,101 | $0 | $517 | 224,384 |
| 2026-07-19 | Option exercise/conversion | Restricted Stock Units | 3,874 | — | — | 23,246 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-19 | Option exercise/conversion (3,874 shares) |
| 2026-07-19 | Tax/exercise-price withholding (1,101 shares) |
| 2026-07-19 | Option exercise/conversion (3,874 shares) |
Keywords
insider transaction, Form 4, HRTX, HERON THERAPEUTICS, INC. /DE/, neutral, William P Forbes
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.